Tamoxifen therapy in recurrent epithelial ovarian carcinoma

Thirty-seven patients with recurrent epithelial ovarian carcinoma were entered into a trial of tamoxifen therapy (10 mg BID) to determine the effect on long-term survival. Thirty-one patients were evaluable with follow-up ranging from 6 to 42 months since initiation of hormonal therapy. All patients...

Full description

Saved in:
Bibliographic Details
Published inGynecologic oncology Vol. 27; no. 2; pp. 208 - 213
Main Authors Weiner, Sheldon A., Alberts, David S., Surwit, Earl A., Davis, John, Grosso, David
Format Journal Article Conference Proceeding
LanguageEnglish
Published San Diego, CA Elsevier Inc 01.06.1987
Elsevier
Subjects
Antineoplastic agents
Biological and medical sciences
Carcinoma - drug therapy
Chemotherapy
Drug Evaluation
Female
Humans
Lymphatic Metastasis
Medical sciences
Ovarian Neoplasms - drug therapy
Pharmacology. Drug treatments
Receptors, Estrogen - metabolism
Recurrence
Tamoxifen - therapeutic use
Time Factors
Antineoplastic agent
Human
Ovary
Recurrence
Chemotherapy
Treatment
Tumor
Tamoxifene
Female genital diseases
Online AccessGet full text

Cover

More Information
Summary:Thirty-seven patients with recurrent epithelial ovarian carcinoma were entered into a trial of tamoxifen therapy (10 mg BID) to determine the effect on long-term survival. Thirty-one patients were evaluable with follow-up ranging from 6 to 42 months since initiation of hormonal therapy. All patients were heavily pretreated with multiple chemotherapeutic regimens (median 3). There was 1 complete responder (3.2%), 2 31 (6.4%) had a partial response, 6 31 (19.3%) had stable disease, and 22 31 (71%) had progressive disease. Twenty-four patients are dead (23 from advanced carcinoma, 1 from cardiac causes); 5 patients are alive with disease; 2 patients are lost to follow-up. Median survival of nonresponders was 7 months versus 16 months for responders (CR + PR + stable disease) ( P = 0.001 life table analysis). Of the 9 responders, 7 had poorly differentiated tumors (grades 3 or 4), and 2 had moderately differentiated tumors (grade 2). Eleven patients had estrogen and progesterone receptor studies (ER, PR). No correlation between response rate and receptor status was evident. We conclude that although significant disease regression is unlikely to result from tamoxifen therapy, there may be a subset of patients who can benefit from the cytostatic properties of hormonal manipulation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0090-8258
1095-6859
DOI:10.1016/0090-8258(87)90294-0